

Table S1. Prevalence of vancomycin-resistant *Enterococcus* isolates from clinical and surveillance samples.

| VRE species | Ward | | | | ICU | | | |
|---------------------|-----------------------------------|-----------------------------------|-------------|----------|-----------------------------------|-----------------------------------|-------------|----------|
| | March 2018 - September 2019 | March 2020 - September 2021 | % change | <i>p</i> | March 2018 - September 2019 | March 2020 - September 2021 | % change | <i>p</i> |
| Clinical | | | | | | | | |
| <i>E. faecium</i> | 0.46 | 0.68 | +50.1 | < 0.001 | 1.48 | 1.90 | +28.6 | 0.094 |
| <i>E. faecalis</i> | 0.01 | 0.01 | +19.4 | 0.439 | 0.04 | 0.02 | -37.5 | 1.000 |
| Surveillance | | | | | | | | |
| <i>E. faecium</i> | 0.45 | 0.42 | -8.2 | 0.424 | 3.75 | 1.31 | -65.1 | < 0.001 |
| <i>E. faecalis</i> | 0.01 | 0.01 | +39.3 | 0.395 | 0.04 | 0.04 | +24.9 | 0.731 |

Values are presented as infection cases/1000 patient-days

VRE, vancomycin-resistant *Enterococcus*; ICU, intensive care unit.

Table S2. Prevalence of carbapenem-resistant *Enterobacteriaceae* isolates from clinical and surveillance samples.

| CRE species | Ward | | | | ICU | | | |
|--------------------------|-----------------------------------|-----------------------------------|----------|----------|-----------------------------------|-----------------------------------|----------|----------|
| | March 2018 - September 2019 | March 2020 - September 2021 | % change | <i>P</i> | March 2018 - September 2019 | March 2020 - September 2021 | % change | <i>P</i> |
| Clinical | | | | | | | | |
| <i>K. pneumoniae</i> | 0.15 | 0.22 | +45.4 | < 0.001 | 0.75 | 1.25 | +67.6 | < 0.001 |
| <i>Escherichia coli</i> | 0.06 | 0.09 | +58.0 | < 0.001 | 0.09 | 0.13 | +36.1 | 0.281 |
| <i>Enterobacter</i> spp. | 0.04 | 0.03 | -36.8 | 0.175 | 0.14 | 0.08 | -42.7 | 0.204 |
| <i>Serratia</i> spp. | 0.01 | 0.01 | +49.2 | 0.251 | 0.07 | 0.08 | +14.5 | 0.611 |
| <i>Klebsiella</i> spp. | 0.01 | 0.01 | -12.5 | 0.991 | 0.05 | 0.07 | +33.8 | 0.451 |
| <i>Citrobacter</i> spp. | 0.01 | 0.01 | +118.8 | 0.06 | 0.02 | 0.03 | +38.8 | 0.713 |
| Others | 0.00 | 0.00 | - | 0.143 | 0.00 | 0.01 | + | 0.219 |
| Surveillance | | | | | | | | |
| <i>K. pneumoniae</i> | 0.29 | 0.44 | +52.4 | < 0.001 | 2.58 | 2.86 | +10.7 | 0.009 |
| <i>Escherichia coli</i> | 0.06 | 0.09 | +45.2 | 0.001 | 0.58 | 0.48 | -17.5 | 0.521 |
| <i>Enterobacter</i> spp. | 0.04 | 0.06 | +23.9 | 0.066 | 0.70 | 0.44 | -38.0 | 0.016 |
| <i>Serratia</i> spp. | 0.00 | 0.00 | +19.4 | 1 | 0.06 | 0.04 | -21.9 | 0.764 |
| <i>Klebsiella</i> spp. | 0.02 | 0.03 | +85.7 | 0.010 | 0.31 | 0.26 | -15.3 | 0.726 |
| <i>Citrobacter</i> spp. | 0.02 | 0.02 | +30.7 | 0.176 | 0.18 | 0.11 | -37.5 | 0.235 |
| Others | 0.00 | 0.00 | +258.1 | 0.327 | 0.01 | 0.03 | +108.2 | 0.428 |

Values are presented as infection cases/1000 patient-days

CRE, carbapenem-resistant *Enterobacteriaceae*; ICU, intensive care unit; *Enterobacter* spp.: *E. cloacae*, *E. cancerogenus*, *E. hormaechei*, *E. kobei*; *Serratia* spp.: *S. liquefaciens*, *S. marcescens*; *Klebsiella* spp.: *K. aerogenes*, *K. oxytoca*, *K. ozaenae*, *K. variicola*; *Citrobacter* spp.: *C. amalonaticus*, *C. braakii*, *C. koseri*, *C. freundii*; Others: *Cronobacter sakazakii* complex, *Hafnia alvei*, *Kluyvera cryocrescens*, *Providencia rettgeri*, *Providencia stuartii*, and *Raoultella planticola*.